Literature DB >> 27924182

A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities.

Suyu Liu1, Jing Ning2.   

Abstract

We propose a Bayesian adaptive dose-finding design for drug combination trials with delayed toxicity. We model the dose-toxicity relationship using the Finney model, a model widely used in drug-drug interaction studies. The intuitive interpretations of the Finney model facilitate incorporating the available prior dose-toxicity information from single-agent trials into combination trials through prior elicitation. We treat unobserved delayed toxicity outcomes as missing data and handle them using Bayesian data augmentation. We conduct extensive simulation studies to examine the operating characteristics of the proposed method under various practical scenarios. Results show that the proposed design is safe and able to select the target dose combinations with high probabilities.

Entities:  

Keywords:  Adaptive design; Combining drugs; Late-onset toxicity; Maximum tolerated dose; Missing data; Phase I trial

Year:  2013        PMID: 27924182      PMCID: PMC5136476          DOI: 10.1214/13-BA839

Source DB:  PubMed          Journal:  Bayesian Anal        ISSN: 1931-6690            Impact factor:   3.728


  17 in total

1.  Dose-finding with two agents in Phase I oncology trials.

Authors:  Peter F Thall; Randall E Millikan; Peter Mueller; Sang-Joon Lee
Journal:  Biometrics       Date:  2003-09       Impact factor: 2.571

2.  Designs for single- or multiple-agent phase I trials.

Authors:  Mark R Conaway; Stephanie Dunbar; Shyamal D Peddada
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

3.  Two-dimensional dose finding in discrete dose space.

Authors:  Kai Wang; Anastasia Ivanova
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

4.  Sequential continual reassessment method for two-dimensional dose finding.

Authors:  Ying Yuan; Guosheng Yin
Journal:  Stat Med       Date:  2008-11-29       Impact factor: 2.373

5.  A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.

Authors:  X Paoletti; A Kramar
Journal:  Stat Med       Date:  2009-10-30       Impact factor: 2.373

6.  Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

Authors:  Sophie Postel-Vinay; Carlos Gomez-Roca; L Rhoda Molife; Bhavesh Anghan; Antonin Levy; Ian Judson; Johann De Bono; Jean-Charles Soria; Stan Kaye; Xavier Paoletti
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

7.  A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents.

Authors:  Thomas M Braun; Shufang Wang
Journal:  Biometrics       Date:  2010-09       Impact factor: 2.571

Review 8.  The search for synergy: a critical review from a response surface perspective.

Authors:  W R Greco; G Bravo; J C Parsons
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

Review 9.  Late effects of radiation therapy in the head and neck region.

Authors:  J S Cooper; K Fu; J Marks; S Silverman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

Review 10.  Late effects of radiation therapy on the gastrointestinal tract.

Authors:  L R Coia; R J Myerson; J E Tepper
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

View more
  4 in total

1.  A dose-finding design for dual-agent trials with patient-specific doses for one agent with application to an opiate detoxification trial.

Authors:  Pavel Mozgunov; Suzie Cro; Anne Lingford-Hughes; Louise M Paterson; Thomas Jaki
Journal:  Pharm Stat       Date:  2021-12-10       Impact factor: 1.894

2.  On the coherence of model-based dose-finding designs for drug combination trials.

Authors:  Yeonhee Park; Suyu Liu
Journal:  PLoS One       Date:  2020-11-30       Impact factor: 3.240

3.  A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs.

Authors:  Chen Li; Hongying Sun; Cheng Cheng; Li Tang; Haitao Pan
Journal:  Contemp Clin Trials Commun       Date:  2022-09-13

4.  Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials.

Authors:  Akihiro Hirakawa; Yuichi Tanaka; Shuhei Kaneko
Journal:  Contemp Clin Trials Commun       Date:  2019-11-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.